Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q28444960)
Watch
English
BRCA1 Mutation
genetic variant
MUTATION
In more languages
edit
Statements
instance of
gene variant
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/185
Loss Of Function Variant
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/185
chromosome
human chromosome 17
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/185
genomic start
41197646
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/185
genomic end
41277500
genomic assembly
Genome assembly GRCh37
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/185
biological variant of
BRCA1
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/185
positive therapeutic predictor for
olaparib
determination method
CIViC evidence level A
rating
CIViC 4-star trust rating
medical condition treated
cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1370
stated in
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
cediranib / olaparib combination therapy
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
ovarian cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1677
stated in
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
cisplatin
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
triple-negative breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1684
stated in
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
olaparib
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
ovarian cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1772
stated in
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
cisplatin
determination method
CIViC evidence level B
rating
CIViC 4-star trust rating
medical condition treated
pancreatic cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/5915
stated in
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
oxaliplatin
determination method
CIViC evidence level B
rating
CIViC 4-star trust rating
medical condition treated
pancreatic cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/5915
stated in
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
rucaparib
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
ovarian cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/6341
stated in
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
olaparib
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
pancreatic cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/5914
stated in
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
carboplatin
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
triple-negative breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1684
stated in
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
negative therapeutic predictor for
olaparib
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
medical condition treated
triple-negative breast cancer
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1775
stated in
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
positive prognostic predictor for
surface epithelial-stromal tumor
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/464
stated in
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
ovarian cancer
determination method
CIViC evidence level B
rating
CIViC 3-star trust rating
1 reference
curator
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/evidence/1675
stated in
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Identifiers
CIViC variant ID
185
1 reference
stated in
CIViC database
retrieved
23 May 2022
reference URL
https://civic.genome.wustl.edu/links/variants/185
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit